# A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

> **NCT05038020** · PHASE2 · TERMINATED · sponsor: **Alkahest, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** AKST4290
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05038020
- **Lead sponsor:** Alkahest, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-17
- **Primary completion:** 2021-12-09
- **Final completion:** 2022-04-19
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study terminated due to safety findings in other AKST4290 studies
- **Last updated:** 2023-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05038020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05038020, "A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT05038020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*